XORTX Welcomes New Member to the Board of Directors

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.

Mr. Treanor is a seasoned pharmaceutical industry executive. He is the current Chief Operating Officer of Pathalys Pharma, Inc., a private company focused on the development of advanced therapeutics to improve the management of late stage chronic kidney disease. He previously served as President, US for Vifor Pharma, an international pharmaceutical company focused on nephrology. Mr. Treanor began his career with large pharmaceutical organizations such as Johnson & Johnson and Abbott Laboratories over 25 years ago but found his niche building early-stage commercial organizations at companies such as Oscient Pharmaceuticals, AMAG Pharmaceuticals, Insulet Corporation and Relypsa Pharmaceuticals. Mr. Treanor currently serves on the board of directors of KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors. He holds a BS in Management from Bryant University and an MBA from Rensselaer Polytechnic Institute.

Anthony Giovinazzo, Chair of XORTX, stated, “We are very pleased to have Patrick Treanor agree to join the XORTX board. His operational and marketing experience in clinical stage pharmaceutical companies and his knowledge of kidney disease are an important resource for XORTX as the Company advances its clinical trials and prepares for commercial program launch. On behalf of the Company, we thank Ian Klassen for his contributions to XORTX over the past three years.”

Patrick Treanor stated, “I am pleased to join the XORTX board at this exciting time as the Company advances towards its potentially pivotal Phase 3 study of XRx-008 in Autosomal Dominant Polycystic Kidney Disease (ADPKD). I look forward to working with my fellow board members and Company management to prepare XORTX for the potential commercialization of XRx-008 and advancing XORTX’s portfolio of drug-based therapies for progressive kidney diseases.”